Literature DB >> 1333351

Factors predicting the acute effect of pamidronate on serum calcium in hypercalcemia of malignancy.

S J Gallacher1, W D Fraser, F C Logue, F J Dryburgh, R A Cowan, I T Boyle, S H Ralston.   

Abstract

In this study we retrospectively reviewed results of the first 9 days of treatment with pamidronate at doses of 30 mg (n = 13), 45 mg (n = 9), and 90 mg (n = 13) in an attempt to see what factors influenced the response of serum calcium to pamidronate. The nadir of serum calcium obtained post treatment was correlated with pretreatment levels of nephrogenous cyclic adenosine monophosphate (NcAMP), the renal tubular threshold for phosphate reabsorption (TmPO4), and the renal tubular threshold for calcium reabsorption (TmCa). Using the post treatment serum calcium levels, patients were divided into "good" and "poor" responders depending on whether a normal serum calcium was obtained. Pretreatment NcAMP was significantly correlated with the magnitude of the response of serum calcium (r = 0.45, P = 0.0001). Pretreatment NcAMP was significantly higher in the poor responders (mean +/- SEM): 65.0 +/- 9.4 nmol/liter GF (poor responders) versus 29.6 +/- 6.3 (good responders), P = 0.004. NcAMP as a predictor of the acute response of serum calcium showed a sensitivity of 93% and a specificity of 72%. Pretreatment TmPO4 was negatively correlated with the serum calcium response post treatment (r = -0.41, P = 0.003). However, though TmPO4 tended to be lower in the poor responders, this was not statistically significant [0.65 mmol/liter GF +/- 0.09 (poor responders) versus 0.76 mmol/liter GF +/- 0.06 (good responders)]. As a predictor of the acute response of serum calcium, TmPO4 was less good with a sensitivity of 70% and specificity of 58%. No significant correlation was present between TmCa and the serum calcium response.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1333351     DOI: 10.1007/bf00296674

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  25 in total

1.  Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP.

Authors:  D Thiébaud; P Jaeger; A F Jacquet; P Burckhardt
Journal:  J Clin Oncol       Date:  1988-05       Impact factor: 44.544

2.  A two-site immunoradiometric assay for PTH(1-84) using N and C terminal specific monoclonal antibodies.

Authors:  F C Logue; B Perry; R S Chapman; I Milne; K James; G H Beastall
Journal:  Ann Clin Biochem       Date:  1991-03       Impact factor: 2.057

3.  Dose of bisphosphonate for hypercalcaemia of malignancy.

Authors:  A R Morton; J Friefeld; F Halperin
Journal:  Lancet       Date:  1990-06-16       Impact factor: 79.321

4.  Chronic high-dose pamidronate in refractory malignant hypercalcaemia.

Authors:  I Judson; F Booth; M Gore; T McElwain
Journal:  Lancet       Date:  1990-03-31       Impact factor: 79.321

5.  Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia.

Authors:  S H Ralston; S J Gallacher; U Patel; F J Dryburgh; W D Fraser; R A Cowan; I T Boyle
Journal:  Lancet       Date:  1989-11-18       Impact factor: 79.321

6.  Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups.

Authors:  A F Stewart; R Horst; L J Deftos; E C Cadman; R Lang; A E Broadus
Journal:  N Engl J Med       Date:  1980-12-11       Impact factor: 91.245

7.  Arginine infusion blocks the action of parathyroid hormone but not arginine vasopressin on the renal tubule in man.

Authors:  D S O'Reilly; W D Fraser; M D Penney; F C Logue; R A Cowan; B C Williams; G Walters
Journal:  J Endocrinol       Date:  1986-12       Impact factor: 4.286

8.  Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.

Authors:  S H Ralston; M D Gardner; F J Dryburgh; A S Jenkins; R A Cowan; I T Boyle
Journal:  Lancet       Date:  1985-10-26       Impact factor: 79.321

9.  Nephrogenous cyclic adenosine monophosphate as a parathyroid function test.

Authors:  A E Broadus; J E Mahaffey; F C Bartter; R M Neer
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

10.  Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow.

Authors:  D E Hughes; B R MacDonald; R G Russell; M Gowen
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

View more
  4 in total

Review 1.  Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone.

Authors:  A J Coukell; A Markham
Journal:  Drugs Aging       Date:  1998-02       Impact factor: 3.923

2.  Decrease of serum calcium concentration and lost influence of calcium on parathyroid hormone release in a patient with primary hyperparathyroidism after treatment with diphosphonates.

Authors:  H Kotzmann; P Bernecker; T Svoboda; B Niederle; A Luger
Journal:  Calcif Tissue Int       Date:  1993-11       Impact factor: 4.333

3.  Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein.

Authors:  J Walls; W A Ratcliffe; A Howell; N J Bundred
Journal:  Br J Cancer       Date:  1994-07       Impact factor: 7.640

4.  High-dose vitamin D metabolite delivery inhibits breast cancer metastasis.

Authors:  Jiaye Liu; Junyi Shen; Chunyang Mu; Yang Liu; Dongsheng He; Han Luo; Wenshuang Wu; Xun Zheng; Yi Liu; Sunrui Chen; Qiuwei Pan; Yiguo Hu; Yinyun Ni; Yang Wang; Yong Liu; Zhihui Li
Journal:  Bioeng Transl Med       Date:  2021-10-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.